key: cord-0692461-twuwjqdc
authors: Torres, Ignacio; Albert, Eliseo; Giménez, Estela; Alcaraz, María Jesús; Botija, Pilar; Amat, Paula; Remigia, María José; Beltrán, María José; Rodado, Celia; Huntley, Dixie; Olea, Beatriz; Navarro, David
title: B and T cell immune responses elicited by the Comirnaty® COVID-19 vaccine in nursing home residents
date: 2021-06-24
journal: Clin Microbiol Infect
DOI: 10.1016/j.cmi.2021.06.013
sha: 46a9734b06a146d4bdc1729c7b5332f969213b23
doc_id: 692461
cord_uid: twuwjqdc

OBJECTIVES: The immunogenicity of the Comirnaty® COVID-19 vaccine is understudied in elderly people with comorbidities. SARS-CoV-2-S-targeted antibody and T cell responses following full vaccination were assessed in nursing home residents. METHODS: Sixty nursing home residents (44 female; age, 53-100 years), of whom 10 had previously been diagnosed of COVID-19, and 18 healthy controls (15 female; age, 27-54 years) were recruited. Pre- and post-vaccination blood specimens were available for quantitation of total antibodies binding SARS-CoV-2 S protein and enumeration of SARS-CoV-2-S-reactive IFN-γ CD4(+) and CD8(+) T cells by flow cytometry. RESULTS: The seroconversion rate in presumably SARS-CoV-2 naïve nursing home residents (41/43; 95.3%), was similar to controls (17/18; 94.4%). A booster effect was documented in post vaccination samples of nursing home residents with prior COVID-19. Plasma antibody levels were higher (P<0.01) in recovered nursing home residents (all 2,500 IU/ml) than in individuals across the other two groups (median, 1,120 IU/ml in naïve nursing home residents and 2,211 IU/ml in controls). A large percentage of nursing home residents had SARS-CoV-2 S-reactive IFN-γ CD8(+) (naïve, 31/49; 63.2%; recovered, 8/10; 80%) or CD4(+) T cells (naïve, 35/49; 71.4%; recovered, 7/10; 70%) at baseline, in contrast to healthy controls (3/17, 17.6% and 5/17; 29%, respectively). SARS-CoV-2 IFN-γ CD8(+) and CD4(+) T-cell responses were documented in 88% (15/17) and all control subjects after vaccination, respectively, but only in 65.5% (38/58) and 22.4% (13/58) of nursing home residents. Overall, the median frequency of SARS-CoV-2 IFN-γ CD8(+) and CD4(+) T cells in nursing home residents decreased in post-vaccination specimens, whereas it increased in controls. CONCLUSION: The Comirnaty® COVID-19 vaccine elicits robust SARS-CoV-2-S antibody responses in nursing home residents. Nevertheless, the rate and frequency of detectable SARS-CoV-2 IFN-γ T-cell responses after vaccination was lower in nursing home residents compared to controls.

The Comirnaty® (Pfizer-BioNTech) COVID-19 vaccine, a nucleoside-modified 57 messenger RNA that encodes the full-length transmembrane S glycoprotein locked in its 58 perfusion conformation, elicits high levels of serum neutralizing antibodies (NtAb), 59 mainly targeting the SARS-CoV-2 receptor-binding domain (RBD), and strong TH 1 -60 skewed functional CD4 + and CD8 + T cell responses in experimental models and humans 61 [1] [2] [3] [4] . The efficacy of the vaccine has been shown to approach 95% in preventing 62 COVID-19 across a wide range of age groups [5] . Real Figure 1 , which shows representative flow cytometry plots) as previously described 106 [11, 12] . 107

Frequency comparisons for categorical variables were carried out using the Fisher exact 109 test. Differences between medians were compared using the Mann-Whitney U-test or 110 the Wilcoxon test for unpaired and paired data, when appropriate. The Spearman rank 111 test was used for correlation analyses between continuous variables. Two-sided exact P-

The median age of participants was 87.5 years (range, 53-100) for nursing home 117 residents and 48.5 years (range, 27 to 60 years) for controls. As shown in 118

Supplementary Table 1 , 51/60 subjects (84%) had one or more comorbidities at 119 enrollment (median, 4; range, 1-7). Baseline blood specimens were collected within one 120

week before first vaccine dose in both nursing home residents and controls. Post-121 vaccination specimens were drawn at a median of 17. 5 days (range, 14-35 days) or 15 122 days (range, 13-35 days) after the second dose in nursing home residents and controls, 123 respectively. 124

No serological evidence of prior SARS-CoV-2 infection was found in 49/59 (83%) of 126 nursing home residents at baseline. Pre-vaccination plasma was not available from one 127 patient. 17% nursing home residents (10/59) had suffered from COVID-19 (nursing 128 home residents recovered). 129

Plasma collected after the second vaccine dose was available for 43 of the 49 nursing 130 home residents with no documented prior infection. One of the remaining six patients 131 died before having received the second dose. Forty-one out of the 43 subjects tested 132 positive by Roche SARS-CoV-2-S immunoassay. All but one specimen tested negative 133 by SARS-CoV-2 N immunoassay, suggesting that one nursing home resident had 134 presumably contracted SARS-CoV-2 infection between the first and the second vaccine 135 dose. Therefore, the overall seroconversion rate in this nursing home resident group was 136 95.3% (41/43). Of interest, plasma specimens from nursing home residents and controls 137 testing negative were run with LIAISON® SARS-CoV-2 TrimericS IgG assay, also 138 returning negative results. All 10 recovered nursing home residents had detectable 139 SARS-CoV-2 S and N-binding antibodies at baseline; one patient died before receiving 140 the second vaccine dose. A booster effect was observed in all nine individuals following 141 full dose vaccination, with a median 33-fold (range, 10 to 600-fold) increase in antibody 142 levels. Seventeen out of 18 controls had SARS-CoV-2 S-binding antibodies after the 143 second vaccine dose, while none tested positive for N-specific antibodies. Accordingly, 144 the seroconversion rate in this subgroup was 94.4% (17/18). As shown in Figure 1 , 145 plasma levels of SARS-CoV-2 S antibodies following complete vaccination were higher 146 (P<0.01) in recovered nursing home residents (all 2,500 IU/ml) than in those 147 presumably SARS-CoV-2 naïve (median 1120 IU/ml; range, 1.08-2,500) or controls 148 (median 2,211 IU/ml; range, 18.4-2,500). In turn, controls displayed higher SARS-149

CoV-2 S antibody levels than SARS-CoV-2 naïve nursing home residents (P=0.05). 150

Among nursing home residents with no documented prior infection, the seroconversion 151 rate was comparable (P>0.99) in individuals presenting either with (33/35; 94%) or 152 without comorbidities (9/9; 100%). Moreover, having a comorbidity did not impact 153 significantly (P=0.14) on SARS-CoV-2-S antibody levels in this population group 154 (Supplementary Figure 2) . 155

Analysis of pre-vaccination blood specimens revealed the presence of SARS-CoV-2 S-157 reactive IFN-γ CD8 + and CD4 + T cells in 31/49 (63%) and 35/49 (71.4%) of naïve 158 nursing home residents and in 8/10 (80%) and 7/10 (70%) of nursing home residents 159 with a history of SARS-CoV-2 infection; these figures were substantially lower in 160 healthy controls (3/17; 17.6%, for CD8 + and 5/17; 29%, for CD4 + T cells) ( Table 1) . 161

Following the second vaccine dose, all control subjects had detectable SARS-CoV-2 S-162 reactive IFN-γ CD4 + T cells and 15/17 (88%) had both IFN-γ CD4 + and CD8 + T cells.

2 IFN-γ CD8 + or CD4 + T cell responses (or both), independently of their baseline 165 SARS-CoV-2 infection status, dropped consistently after vaccination (except for CD8 + 166 T cells in nursing home residents without prior infection), as shown in Table 1 . In fact, 167 the percentage of responders was lower in nursing home residents than in controls 168 (P=0.32 for CD8 + and P<0.001 for CD4 + ). Among nursing home residents, the 169 percentage of participants displaying detectable SARS-CoV-2 CD8 + and CD4 + T cells 170

following vaccination was comparable across presumably SARS-CoV-2 naïve and 171 recovered (P=0.99 for CD8 + and P=0.20 for CD4 + ). Interestingly, both loss and de novo 172 acquisition of detectable SARS-CoV-2 IFN-γ CD8 + or CD4 + T-cell responses were 173 observed in some nursing home residents, particularly in CD8 + T cells ( Figure 2 ). 174

As shown in Figure 3 and Table 2 Table 2 Table 1 

Study group 

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

Safety 307 and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

BNT162b 310 vaccines protect rhesus macaques from SARS-CoV-2

Safety 313 and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Impact and 316 effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and 317 COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination 318 campaign in Israel: an observational study using national surveillance data

Interim 321 findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital 322 admissions in Scotland: a national prospective cohort study. Lancet 323 BNT162b2 vaccination

Efficacy and safety of COVID-19 vaccines in 333 older people

WHO International Standard and Reference Panel for anti-SARS

CoV-2-reactive interferon-gamma-producing CD8+ T cells in patients hospitalized with 339 coronavirus disease 2019

SARS-CoV-2-Specific Cell-Mediated Immunity in Kidney Transplant 342

Recipients Recovered from COVID-19

Quantitative measurement of anti-SARS-CoV-345 2 antibodies: Analytical and clinical evaluation

Head-to-head comparison of 347 two rapid high-throughput automated electrochemiluminescence immunoassays 348 targeting total antibodies to the SARS-CoV-2 nucleoprotein and spike protein receptor 349 binding domain

Poor antigen-specific responses to the second BNT162b2 mRNA vaccine dose 356 in SARS-CoV-2-experienced individuals medRxiv

T cell 359 response to SARS-CoV-2 infection in humans: A systematic review

Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild 363 COVID-19

Targeting Inflammation and Immunosenescence to

Improve Vaccine Responses in the Elderly

Differential T cell reactivity to endemic coronaviruses and SARS-CoV-2 in 368 community and health care workers

μg/ml) was added for the last 4 h of incubation. Blood was then lysed (BD FACS 401 lysing solution) and frozen at −80°C until tested. On the day of testing, stimulated blood 402 was thawed at 37°C, washed, permeabilized (BD permeabilizing solution) and stained 403 with a combination of labeled mAbs

Appropriate positive 405 (phytohemagglutinin) and isotype controls were used. Cells were then washed, 406 resuspended in 200 μL of 1% paraformaldehyde in PBS

FACSCanto flow cytometer using DIVA v8 software

CD3 + /CD8 + or CD3 + /CD4 + events were 409 gated and then analyzed for IFN-γ production. All data were corrected for background

IFN-γ production (FITC-labelled isotype control antibody) and expressed as a 411 percentage of total CD8 + or CD4 + T cells

Supplementary Figure 2. SARS-CoV-2-S plasma antibody levels as measured by

Roche Elecsys® Anti-SARS-CoV-2 S immunoassay in nursing home residents (NHR)